Abivax stock surges as new trial data ease cancer fears over bowel disease drug
New data from a Phase 3 maintenance study showed malignancy rates in line with what ulcerative colitis patients normally experience
Overview
New data from a Phase 3 maintenance study showed malignancy rates in line with what ulcerative colitis patients normally experience
Source
Originally published at qz.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.
